(Copper gluconate + disulfiram) is under clinical development by Cantex Pharmaceuticals and currently in Phase I for Refractory Multiple Myeloma. According to GlobalData, Phase I drugs for Refractory Multiple Myeloma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how (Copper gluconate + disulfiram)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

(Copper gluconate + disulfiram) overview

Copper gluconate in a fixed dose combination with disulfiram (FDC) is under development for the treatment of relapse and refractory multiple myeloma. It is administered through subcutaneous route and oral (capsules) route. The drug candidate acts by targeting the CXCL12-CXCR4 axis. It was also under development for the treatment of newly diagnosed glioblastoma multiforme, breast cancer, prostate cancer, metastatic triple-negative breast cancer, brain metastases, metastatic non-small cell lung cancer, acute radiation syndrome, recurrent glioblastoma multiforme, recurrent pediatric sarcoma, metastatic pancreatic cancer and metastatic castration-resistant prostate cancer.

Cantex Pharmaceuticals overview

Cantex Pharmaceuticals, formerly ParinGenix is a clinical stage biopharmaceutical company. The company discovers and develops proprietary pharmaceuticals for the treatment of cancers and other disorders. Its pipeline products include CX-01 a proprietary combination of disulfiram and copper that is in Phase II clinical trial for the treatment of recurrent glioblastoma; and completed Phase 1 trial in metastatic prostate cancer and breast cancer. Cantex Pharmaceuticals also develops CX-01 a polysaccharide used for the treatment of acute myeloid leukemia (AML), traumatic brain injury and other blood disorders. The company offers its products across the US. Cantex Pharmaceuticals is headquartered in Weston, Florida, the US

For a complete picture of (Copper gluconate + disulfiram)’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.